Eprobemide

Source: Wikipedia, the free encyclopedia.
Eprobemide
Clinical data
Trade namesBefol (RU)
Other namesBefol
Routes of
administration		Oral
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 4-Chloro-N-[3-(4-morpholinyl)propyl]benzamide
JSmol)
  • C1COCCN1CCCNC(=O)C2=CC=C(C=C2)Cl
  • InChI=1S/C14H19ClN2O2/c15-13-4-2-12(3-5-13)14(18)16-6-1-7-17-8-10-19-11-9-17/h2-5H,1,6-11H2,(H,16,18)
  • Key:YYFGRAGNYHYWEZ-UHFFFAOYSA-N

Eprobemide (

reversible inhibitor of monoamine oxidase A[2][3] that exhibits selective action on serotonin deamination.[4] Eprobemide differs from moclobemide only in the linker that connects the morpholine fragment with the chlorobenzamide — moclobemide has two carbon atoms while eprobemide has three. Its registration was cancelled on December 30, 2003.[5]

References

  1. ISBN 978-0412466304
    .
  2. PMID 2054504
    .
  3. S2CID 29121452
    .
  4. ^ "Eprobemide". ChemIDplus.
  5. ^ "Befol". 4DOKTOR.RU Drug Information Handbook (in Russian). Retrieved 4 February 2014.
drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Eprobemide&oldid=1185785614"